TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A South Korean randomized trial found that 88.2% of rheumatoid arthritis patients assigned to a structured 50% reduction in targeted DMARD exposure remained in low disease activity at 24 weeks, compared with 89.6% continuing usual doses. The result met the trial’s noninferiority criteria, but follow-up was short, some secondary measures favored usual dosing, and the findings do not establish that tapering is appropriate for every patient.
A 348-patient randomized trial in South Korea found that a structured reduction of targeted disease-modifying antirheumatic drug (DMARD) exposure by half was noninferior to usual dosing for maintaining low rheumatoid arthritis disease activity over 24 weeks. Low disease activity was maintained by 88.2% of patients assigned to tapering and 89.6% of those who continued their doses, researchers reported in Arthritis & Rheumatology.
The study enrolled people whose rheumatoid arthritis (RA) had remained at low disease activity for at least six months while they were taking a biologic or targeted oral medication. Participants were randomly assigned either to a planned reduction targeting 50% less drug exposure or to continue their existing regimen. The average age was 56, and 82.5% of participants were women; average disease duration exceeded 11 years.
The difference between groups in the primary outcome was -1.43 percentage points, with a 95% confidence interval from -8.09 to 5.23. The researchers said this met their prespecified noninferiority criteria. The primary measure was the DAS28-ESR score; a score above 3.2 meant a patient was no longer considered to have low disease activity. The study assessed outcomes at week 24.
The reduction method depended on the medication. For biologics, researchers extended the interval between doses in two steps; for the JAK inhibitors tofacitinib and baricitinib, they reduced the dose or frequency. The aim in each case was 50% lower exposure, not stopping treatment. The researchers described the approach as potentially feasible for selected patients when paired with monitoring and the option to raise treatment again if disease activity worsens.
A Dose Reduction, Not Drug Withdrawal
Targeted RA medicines can be costly and may cause side effects, so a safe reduction could lessen treatment burden for some people whose disease is controlled. This trial offers comparative evidence for a planned half-dose exposure strategy, rather than complete withdrawal, which has had mixed results in prior DMARD studies.
The findings do not mean that patients can safely change doses on their own or that tapering carries no risk. The difference in the primary outcome was small, but other disease-activity measures, including DAS28-ESR, SDAI and CDAI, rose slightly in the tapering group while remaining broadly unchanged in the usual-dose group. Those secondary results make ongoing monitoring and individualized decisions relevant. The trial does not establish long-term effects on joint damage, flares, safety or quality of life.
rheumatoid arthritis DMARD dose reduction
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How the Korean Trial Was Run
Questions about reducing biologic and targeted oral DMARD doses have been debated because maintaining disease control must be balanced against medication burden. Earlier tapering and withdrawal studies have not produced uniform results. The South Korean research team led by Shin-Seok Lee, MD, PhD, tested a structured reduction protocol in patients already at low disease activity, rather than asking participants to stop treatment altogether.
Participants used tumor necrosis factor inhibitors, non-TNF biologics or JAK inhibitors. The study included adalimumab or etanercept for 42% of patients and a JAK inhibitor for 37%; the remainder used tocilizumab or abatacept. For biologic users assigned to tapering, the dose interval was extended in two steps, with the second change at week 12. Those patients therefore had their reduced schedule for only the latter half of the 24-week study. JAK inhibitor dose changes began immediately and continued through week 24.
“The structured tapering strategy … appears to be a feasible treatment approach in patients with RA who have achieved sustained low disease activity.”
— Shin-Seok Lee, MD, PhD, and colleagues, in the study report
biologic medication tapering for RA
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Long-Term Effects Remain Unknown
The study lasted six months, and biologic users assigned to reduce doses followed the lower-exposure schedule for only about 12 weeks before the primary assessment. The trial therefore cannot show whether control would persist over a longer period, whether joint damage might progress, or how cumulative safety outcomes compare.
Some secondary disease-activity scores moved slightly in the direction of worse control with tapering. Researchers also found that patients taking JAK inhibitors were less likely than those taking TNF blockers to maintain low disease activity at week 24, with an adjusted odds ratio of 0.278 and P=0.048. That finding came from an analysis of 13 potential predictors and needs confirmation. The trial was unblinded, and its results do not settle which patients or medications are best suited to dose reduction.
As an affiliate, we earn on qualifying purchases.
Longer Follow-Up Is Needed
The next evidence needed is longer follow-up tracking disease activity, flares, medication increases, radiographic progression and safety outcomes. Further research could also test whether the differences between drug classes persist and identify which patient characteristics predict a successful reduction.
For now, the trial supports discussion of monitored tapering as a possible option for some people with sustained low disease activity, rather than a blanket change in RA treatment. Decisions about any dose adjustment should be made with the treating clinician, who can assess disease history, medication type and a plan for responding if symptoms or measured disease activity worsen.
RA disease activity monitoring tools
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the trial find?
At week 24, 88.2% of the tapering group and 89.6% of the usual-dose group remained in low disease activity. The researchers reported that the result met the study’s prespecified noninferiority criteria.
Did participants stop taking their RA medicines?
No. The study tested a planned reduction to about half the usual drug exposure, using lower doses or longer intervals between doses. It did not test stopping treatment entirely.
Does this mean patients should reduce their doses?
No. The findings apply to a selected study group and do not establish that tapering is right for every patient. Any dose change should be discussed with the treating clinician and paired with monitoring.
What are the main limitations?
The study lasted six months, and biologic users had the reduced schedule for only about half that period. Some secondary measures leaned toward usual dosing, and longer-term effects on joint damage, durability and cumulative safety remain unknown.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
